APT Medical

APT Medical Equity

The The Equity of APT Medical (688617.SS) as of Oct 21, 2026 is 3.09 B CNY. In the previous year, The Equity was 2.52 B CNY — a change of 22.74% (higher).

Equity

3.09 BCNY

YoY

22.74%

Last updated:

In 2025, APT Medical's equity was 3.09 B CNY, a 22.74% increase from the 2.52 B CNY equity in the previous year.

The APT Medical Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
269.84 M CNY
Jan 1, 2019
349.59 M CNY
Jan 1, 2020
460.36 M CNY
Jan 1, 2021
1.78 B CNY
Jan 1, 2022
1.76 B CNY
Jan 1, 2023
1.91 B CNY
Jan 1, 2024
2.52 B CNY
Jan 1, 2025
3.09 B CNY
The APT Medical Equity history
YEAREquityYoY
3.09 BCNY+22.74%
2.52 BCNY+31.94%
1.91 BCNY+8.16%
1.76 BCNY-0.83%
1.78 BCNY+286.25%
460.36 MCNY+31.69%
349.59 MCNY+29.55%
269.84 MCNY+25.99%
214.18 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

APT Medical Stock analysis

What does APT Medical do? APT Medical Inc generates revenue through the research, development, production, and sale of electrophysiology, coronary access, and peripheral vascular intervention medical devices. The company offers electrophysiological electrode catheters, controllable radiofrequency ablation electrode catheters, and multichannel electrophysiological systems under its electrophysiology product line. Its coronary access segment includes guide wires, micro catheters, balloons, contrast guide wires, and catheters. Peripheral vascular intervention products address peripheral vascular diseases and are sold domestically and internationally. The firm also engages in original equipment manufacturer (OEM) business, producing products for other brands. Domestic and overseas markets are the primary sales channels for all product segments. The company's electrophysiology products target healthcare providers specializing in cardiac procedures, while coronary access devices serve interventional cardiologists and vascular surgeons. Peripheral vascular intervention solutions are marketed to hospitals and clinics treating vascular conditions. OEM partnerships allow APT Medical to supply components to other medical device manufacturers without direct branding. These segments collectively drive revenue through direct sales to healthcare institutions and international distributors. APT Medical Inc's product portfolio includes electrophysiological systems and coronary access tools that cater to specific medical specialties. The firm's peripheral vascular intervention products are designed for treating conditions like peripheral artery disease. OEM business contributes to revenue by manufacturing components for other companies' branded products. Domestic market sales and overseas distribution networks form the core of the company's commercial strategy, with no mention of specific customer names or financial figures beyond the employee count. APT Medical is one of the most popular companies on Eulerpool.

Equity Details

Analyzing APT Medical's Equity

APT Medical's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding APT Medical's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating APT Medical's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

APT Medical's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in APT Medical’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about APT Medical stock

The Equity of APT Medical is 3.09 B CNY in 2025.

The Equity of APT Medical changed from 2.52 B CNY to 3.09 B CNY, representing a 22.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity APT Medical since 2006 – with annual values, charts, and detailed analysis.

The Equity's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's APT Medical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — APT Medical

All Key Metrics — APT Medical